Page last updated: 2024-11-03

ritanserin and Lymphoproliferative Disorders

ritanserin has been researched along with Lymphoproliferative Disorders in 1 studies

Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.
ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.

Lymphoproliferative Disorders: Disorders characterized by proliferation of lymphoid tissue, general or unspecified.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Velnati, S1
Ruffo, E1
Massarotti, A1
Talmon, M1
Varma, KSS1
Gesu, A1
Fresu, LG1
Snow, AL1
Bertoni, A1
Capello, D1
Tron, GC1
Graziani, A1
Baldanzi, G1

Other Studies

1 other study available for ritanserin and Lymphoproliferative Disorders

ArticleYear
Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening.
    European journal of medicinal chemistry, 2019, Feb-15, Volume: 164

    Topics: Cell Death; Computer Simulation; Diacylglycerol Kinase; Drug Evaluation, Preclinical; Humans; Lympho

2019